Abstracts tagged "Biologics and ankylosing spondylitis (AS)"

Abstract Number: 1258 • 2019 ACR/ARP Annual Meeting
Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial
John Reveille¹, Atul Deodhar ², Diane Harrison ³, Elizabeth Hsia ⁴, Eric K H Chan ³, Shelly Kafka ⁵, Kim Hung Lo ³, Lilianne Kim ³ and Chenglong Han ³, ¹University of Texas McGovern Medical School, Houston, ²Oregon Health & Science University, Portland, OR, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: In patients with ankylosing spondylitis (AS), IV administration of the anti-TNFa antibody golimumab (GLM-IV) resulted in improvements in composite measures of various aspects of…
Abstract Number: 2498 • 2017 ACR/ARHP Annual Meeting
Rheumatologists Use Different Cut-Offs for Disease Activity in Real Life – the Experience with Golimumab in Ankylosing Spondylitis- Subanalysis from a Non-Interventional German Study
Jürgen Braun¹, Xenofon Baraliakos², Uta Kiltz¹, Klaus Krüger³, Gerd R. Burmester⁴, Siegfried Wassenberg⁵ and Matthias H. Thomas⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Praxiszentrum St. Bonifatius München, München, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁵Rheumazentrum Ratingen, Ratingen, Germany, ⁶Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: International recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) suggest a BASDAI level of disease activity of ≥4 to indicate treatment…
Abstract Number: 2861 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns of Subcutaneous Biologic Agent Use Among Patients with Ankylosing Spondylitis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Background/Purpose: Ankylosing spondylitis (AS) is characterized by chronic debilitating inflammation of the spine and/or sacroiliac joints. Several biologic agents have been approved for the treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].